Assenagon Asset Management S.A. Has $1.56 Million Position in OPKO Health, Inc. (NASDAQ:OPK)

Assenagon Asset Management S.A. raised its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK) by 9.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 935,100 shares of the biotechnology company’s stock after purchasing an additional 78,362 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.14% of OPKO Health worth $1,563,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Barclays PLC boosted its stake in OPKO Health by 68.7% in the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company’s stock valued at $1,347,000 after purchasing an additional 373,032 shares during the period. Bank of America Corp DE lifted its holdings in shares of OPKO Health by 94.7% during the fourth quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company’s stock worth $855,000 after buying an additional 282,844 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after acquiring an additional 949,671 shares during the period. Norges Bank acquired a new position in shares of OPKO Health in the fourth quarter valued at about $1,657,000. Finally, Millennium Management LLC increased its position in OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 2,112,382 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the company’s stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the purchase, the chief executive officer now owns 213,651,448 shares of the company’s stock, valued at approximately $363,207,461.60. The trade was a 0.07% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired a total of 500,000 shares of company stock worth $775,000 over the last 90 days. Insiders own 49.69% of the company’s stock.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.29 on Wednesday. OPKO Health, Inc. has a 1 year low of $1.19 and a 1 year high of $2.04. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -18.43 and a beta of 1.39. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28. The company’s 50 day simple moving average is $1.35 and its 200 day simple moving average is $1.52.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The business had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The company’s revenue for the quarter was down 13.7% on a year-over-year basis. As a group, research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on OPK shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. Finally, JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They set a “neutral” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.